Hwang, I.G., Kang, J.H., Oh, S.Y., Lee, S., Kim, S.H., Song, K.H., . . . Kim, H.J. (2016). Phase II trial of epidermal growth factor ointment for patients with erlotinib-related skin effects. Supportive Care in Cancer, 24, 301–309.
To evaluate the effect of epidermal growth factor (EGF) ointment on quality of life (QOL) and erlotinib-related skin effects (ERSEs) in patients with non-small cell lung cancer and pancreatic cancer
EGF ointment containing 1 ppm of nepidermin was applied evenly to skin lesions twice daily for patients with grade 2 or greater lesions.
PHASE OF CARE: Active treatment
Phase II, open-label, noncomparative, multicentered trial
EGF ointment was effective for ERSEs regardless of patient gender, age, type of tumor, and dosage of erlotinib and seems to improve all kinds of ERSEs.
Nursing education, interventions, and additional randomized, controlled studies are needed to elucidate the effectiveness of EGF ointment on ERSEs and QOL in patients with non-small cell lung cancer and pancreatic cancer.